Suppr超能文献

人乳头瘤病毒16型L1主要衣壳蛋白中自然发生的单氨基酸取代:抗体介导中和敏感性的改变

Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.

作者信息

Ning Tingting, Wolfe Aaron, Nie Jianhui, Huang Weijin, Chen Xiaojiang S, Wang Youchun

机构信息

Graduate School of Peking Union Medical College.

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.

出版信息

J Infect Dis. 2017 Oct 17;216(7):867-876. doi: 10.1093/infdis/jix274.

Abstract

BACKGROUND

Each vaccine for human papillomavirus type 16 (HPV16) has been developed on the basis of a single variant, and whether these vaccines can prevent infection due to naturally occurring variants was not clear.

METHODS

To examine this question, constructs of 39 naturally occurring single amino acid substitutions in L1 were generated for pseudovirion production, based on the analysis of 1204 HPV16 L1 protein sequences from the National Center for Biotechnology Information and Papilloma Virus Episteme.

RESULTS

Thirty-one of 39 HPV16 L1 mutants produced infectious pseudovirions that exhibited similar particle-to-infectivity ratios, compared with reference pseudovirions. Twenty-one of 31 pseudovirion-producing mutants showed different susceptibilities to monoclonal antibodies, with 6 resulting in complete loss of reactivity to some of the tested monoclonal antibodies. The vaccinated sera neutralized all 31 variants. Mean neutralization titers of most variants changed by approximately 4-fold, compared with the reference pseudovirions, with the C428W and K430Q mutations displaying 9-fold and 11-fold lower susceptibilities, respectively, to neutralization by the sera than the reference pseudovirions.

CONCLUSIONS

These results suggest that the current HPV vaccines may not offer equal protection against all of the naturally occurring HPV16 variants discovered so far.

摘要

背景

每种16型人乳头瘤病毒(HPV16)疫苗都是基于单一变体研发的,而这些疫苗能否预防自然发生的变体感染尚不清楚。

方法

为了研究这个问题,在对来自美国国立生物技术信息中心和乳头瘤病毒知识库的1204个HPV16 L1蛋白序列进行分析的基础上,构建了39个L1中自然发生的单氨基酸替代物用于假病毒生产。

结果

39个HPV16 L1突变体中有31个产生了感染性假病毒,与对照假病毒相比,其表现出相似的颗粒感染率。31个产生假病毒的突变体中有21个对单克隆抗体表现出不同的敏感性,其中6个导致对某些测试单克隆抗体的反应性完全丧失。接种疫苗的血清中和了所有31种变体。与对照假病毒相比,大多数变体的平均中和滴度变化约4倍,C428W和K430Q突变体对血清中和的敏感性分别比对照假病毒低9倍和11倍。

结论

这些结果表明,目前的HPV疫苗可能无法为迄今发现的所有自然发生的HPV16变体提供同等保护。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验